Compounded tirzepatide: side effects and safety

Tirzepatide side effects, with rates

The best evidence for what a compounded tirzepatide product will do is the label of the approved one, because it is the same molecule and because no compounded version has been studied. The table below is from Zepbound's own trials — 2,519 patients on the drug, 958 on placebo, over 72 weeks. Every reaction listed occurred in at least 2% of patients and more often than on placebo.

• Most of it is gastrointestinal, and most of it is worst after a dose increase. That is why every label escalates slowly and tells prescribers to pause rather than push through.
• Nausea does not keep rising with dose. It peaked at 10 mg in these trials; vomiting and diarrhea did continue to climb.
• Hair loss is real and rarely mentioned in marketing — 4–5% against 1% on placebo. It is usually the kind that follows rapid weight loss rather than a direct drug effect.
• In the diabetes trials the rates are lower — Mounjaro reported nausea at 12–18% against 4% on placebo — largely because those trials used different patients and slower escalation.

The serious risks, and who cannot take it

These apply to any tirzepatide product, compounded or not. They are the parts of the label a prescriber is supposed to go through with you, and a provider that never mentions them is not doing that job.

• Boxed warning. In rats, tirzepatide caused dose-dependent and treatment-duration-dependent thyroid C-cell tumors. Whether it causes them in humans, including medullary thyroid carcinoma, is unknown.
• Contraindicated for anyone with a personal or family history of medullary thyroid carcinoma, anyone with Multiple Endocrine Neoplasia syndrome type 2, and anyone who has had a serious hypersensitivity reaction to tirzepatide.
• Acute pancreatitis — persistent severe abdominal pain, often radiating to the back, with or without vomiting. Stop and seek care.
• Gallbladder disease — pain in the upper right abdomen, fever, or yellowing of the skin or eyes.
• Acute kidney injury from dehydration — vomiting and diarrhea that you cannot keep ahead of can damage the kidneys. Fluids matter more on this drug than off it.
• Hypoglycemia if combined with insulin or a sulfonylurea; those doses usually need reducing.
• Severe gastrointestinal reactions. The label says tirzepatide is not recommended in severe gastroparesis.
• Pulmonary aspiration under anesthesia. Because the drug slows stomach emptying, food can be aspirated during general anesthesia or deep sedation. Tell any surgeon, dentist or anesthetist that you take it.
• Diabetic retinopathy. If you have it, tell the prescriber; rapid improvement in blood sugar can worsen it.
• Pregnancy. Based on animal studies, tirzepatide may cause fetal harm. Oral contraceptives can also be less reliable around dose changes — the label advises a non-oral method or an added barrier method for four weeks after starting and after each dose increase.

Not medical advice, and not a substitute for reading the label or talking to a clinician who knows your history. The full prescribing information is linked in the sources below.

What the FDA has recorded about the compounded version

Everything above is about tirzepatide. The next three sections are about what changes when a pharmacy makes it.

The FDA's position on the category is unambiguous: "Compounded drugs are not FDA approved. This means the agency does not review compounded drugs for safety, effectiveness or quality before they are marketed." That holds even for products from 503B outsourcing facilities, which are FDA-registered and inspected.

As of 31 May 2026 the agency had received more than 730 reports of adverse events associated with compounded tirzepatide, alongside 990 for compounded semaglutide. It adds that the real number is likely higher, because "federal law does not require state-licensed pharmacies that are not outsourcing facilities to submit adverse events to FDA".

The FDA does not publish how many of those reports involved hospitalisation or death; it says only that some required hospitalisation. A report is also not proof of causation. What the number establishes is that this is a monitored problem with an incomplete monitoring system, not that a specific proportion of patients is harmed.

The dosing error is the documented hazard

Zepbound and Mounjaro come as fixed-dose pens and vials: the device is the dose. A compounded product usually arrives as a multi-dose vial at a concentration the pharmacy selected — 10 mg/mL and 17 mg/mL are common — and each dose is drawn with an insulin syringe marked in "units".

The FDA's 2024 alert on compounded injectable GLP-1s, still current, describes what goes wrong. Patients "administered five to 20 times more than the intended dose". Someone told to draw 5 units (0.05 mL) drew 50. A prescriber wrote "25 units" meaning 0.25 mg, which is 5 units. Another wrote 20 units when 2 were intended, and three patients received it.

The reported consequences were "gastrointestinal effects (e.g., nausea, vomiting, abdominal pain), fainting, headache, migraine, dehydration, acute pancreatitis and gallstones", some requiring hospital care. The agency names the cause as confusion between millilitres, milligrams and units, made worse by vials of varying concentrations and by patients who have never drawn up an injection before.

The FDA has also flagged the opposite pattern: patients "prescribed compounded semaglutide or tirzepatide products in doses beyond what is in the FDA-approved drug label" — more per dose, more often, or escalated faster than any label allows.

If you use a compounded product: get your dose written in the same units marked on your syringe, and check the concentration printed on every new vial before the first injection from it. Concentrations change between batches and between pharmacies.

What is in the vial, and where it came from

Compounded tirzepatide contains the active ingredient, a sterile diluent — usually bacteriostatic water — and sometimes an additive. Vitamin B12 is the most common, marketed as easing nausea; glycine and niacinamide also appear. Those additions are often there for a legal reason as much as a clinical one, because a product must differ from the approved drug to be compounded lawfully now that the shortage has ended.

Two sourcing questions matter more than the additives. The form of the ingredient: approved products use tirzepatide base, and a provider should be able to confirm that is what its pharmacy uses. The FDA has warned specifically about semaglutide salt forms — semaglutide sodium and acetate — as different active ingredients with no lawful basis in compounding, and the same principle applies to any substituted form.

Where the raw ingredient came from: since September 2025 the FDA has maintained a "Green List" of acceptable GLP-1 active-ingredient suppliers, backed by Import Alert 66-80, which allows shipments from unlisted sources to be detained at the border.

Outside pharmacy entirely, tirzepatide is sold by "research peptide" sellers, labelled not for human consumption and shipped with dosing instructions. The FDA warns those products may contain the wrong ingredients, too much, too little or no active ingredient at all. Nothing on this page applies to them.

What nobody can tell you

No compounded tirzepatide product has been through a clinical trial. The side-effect rates on this page, and the weight-loss percentages you see quoted anywhere, were measured on Lilly's product. A pharmacy version at a different concentration is expected to behave similarly if everything else is right — but "expected" is not "tested".

Quality varies by pharmacy and is not visible from the outside. A 503A pharmacy is overseen by a state board and is not subject to the FDA's manufacturing rules; a 503B facility is FDA-inspected and must follow good manufacturing practice. Both produce unapproved drugs. Which one made yours is a question with an answer.

The reporting is incomplete by design, so the 730-plus figure is a floor.

How to lower the risk

The checks an approved product comes with have to be done by you, or by someone you trust, with this one.

• Confirm the dose and the concentration in writing before the first injection, in the units marked on your syringe.
• Re-check on every new vial. A new concentration turns the same "units" into a different dose.
• Escalate only as the prescriber set it. Faster is not better, and the FDA has flagged off-label escalation specifically.
• Ask which pharmacy compounded it and whether the ingredient is tirzepatide base from a Green List supplier.
• Keep fluids up during the first weeks and after every dose increase — dehydration is the route from ordinary side effects to a serious one.
• Never reuse or share a needle or syringe, and store the vial as the pharmacy instructed.
• Report side effects to the FDA through MedWatch. With a state-licensed compounding pharmacy, your report may be the only one the agency receives.
• Check the provider itself. Every profile in our directory records licensing, the pharmacy partner where it is published, and any FDA or state action, with sources and dates.